Market Research Logo

Global Anticoagulants Market (2018-2022 Edition)

Global Anticoagulants Market (2018-2022 Edition)

Scope of the Report

The report entitled “Global Anticoagulants Market (2018-2022 Edition)” provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by treatment, by segment, and by products.

The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales.

A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.

Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2018-2022, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.

Company Coverage

Bayer
BMS/Pfizer
Boehringher Ingelheim
Daiichi Sankyo

Regional Coverage

The US

Executive Summary

Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.

The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.

The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2018-2022, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.


1. Executive Summary
2. Introduction
2.1 Overview of Anticoagulants
2.1.1 Types of Anticoagulants
Table 1: Types of Anticoagulants
Table 2: Unfractionated Heparin vs Low Molecular Weight Heparin
2.1.2 Novel Oral Anticoagulants
Table 3: List of Intravenous/Subcutaneous Anticoagulants
Table 4: List of Oral Anticoagulants (NOCAs)
3. Global Market Analysis
3.1 Global Anticoagulants Market Analysis
3.1.1 Global Anticoagulants Market by Value
Table 5: Global Anticoagulants Market by Value; 2013-2017 (US$ Billion)
Table 6: Global Anticoagulants Market by Value; 2017-2022 (US$ Billion)
3.1.2 Global Anticoagulants Market Share by Treatment
Table 7: Global Anticoagulants Market Share by Treatment; 2015 (Percentage, %)
3.1.3 Global Anticoagulants Market Share by Segment (Oral Anticoagulants and others)
Table 8: Global Anticoagulants Market Share by Segment; 2017 (Percentage, %)
3.1.4 Global Anticoagulants Market Share by Products (Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa, and Savaysa)
Table 9: Global Anticoagulants Market Share by Products; 2017 (Percentage, %)
4. Global Anticoagulants Product Analysis
4.1 Injectable Anticoagulants Product Analysis
4.1.1 Global Lovenox Market by Value
Table 10: Global Lovenox Market by Value; 2012-2017 (US$ Billion)
4.1.2 Global Arixtra Market by Value
Table 11: Global Arixtra Market by Value; 2015-2017 (US$ million)
4.2 Oral Anticoagulants Product Analysis
4.2.1 Global Xarelto Market by Value
Table 12: Global Xarelto Market by Value; 2016-2022 (US$ Billion)
4.2.2 Global Eliquis Market by Value
Table 13: Global Eliquis Market by Value; 2016-2022 (US$ Billion)
4.2.3 Global Pradaxa Market by Value
Table 14: Global Pradaxa Market by Value; 2016-2022(US$ Billion)
4.2.4 Global Savaysa Market by Value
Table 15: Global Savaysa Market by Value; 2016-2022 (US$ Million)
5. Regional Analysis
5.1 The US Anticoagulants Market Analysis
5.1.1 The US Anticoagulants Market by Value
Table 16: The US Anticoagulants Market by Value; 2016-2022(US$ Billion)
5.1.2 The US Anticoagulants Market by Products (Xarelto, Eliquis, Pradaxa, and Savaysa)
Table 17: The US Anticoagulants Market by Products; 2017 (Percentage, %)
5.1.3 The US Xarelto Market by Value
Table 18: The US Xarelto Market by Value; 2016-2022(US$ Billion)
5.1.4 The US Eliquis Market by Value
Table 19: The US Eliquis Market by Value; 2016-2022(US$ Billion)
5.1.5 The US Pradaxa Market by Value
Table 20: The US Pradaxa Market by Value; 2016-2022(US$ Million)
5.1.6 The US Savaysa Market by Value
Table 21: The US Savaysa Market by Value; 2016-2022(US$ Million)
6. Competitive Landscape
6.1 Global Top Oral Anticoagulants by Sales
Table 22: Global Top Oral Anticoagulants by Sales; 2017 (US$ Billion)
6.2 Global Anticoagulants Market Players by Product Comparison
Table 23: Global Anticoagulants Market Players by Product Comparison
7. Company Profile
7.1 Bayer Group
7.1.1 Business Overview
Table 24: Bayer Group Product and Activities of Pharmaceutical Segment
Table 25: Xarelto Research and Development Project (Phase III)
7.1.2 Financial Overview
Table 26: Bayer Group Net Sales; 2012-2017 (US$ Billion)
Table 27: Bayer Group Net Sales by Segment; 2017 (Percentage, %)
Table 28: Bayer Group Net Sales by Geography; 2017 (Percentage, %)
7.1.3 Business Strategy
7.2 BMS/Pfizer
7.2.1 Business Overview
7.2.2 Financial Overview
Table 29: BMS-Pfizer Alliance Revenue; 2014-2017 (US$ Billion)
Table 30: BMS Revenue by Geography; 2017 (Percentage, %)
Table 31: BMS Revenue by Product; 2017 (Percentage, %)
7.2.3 Business Strategy
7.3 Boehringher Ingelheim
7.3.1 Business Overview
Table 32: Boehringher Ingelheim Product Review; 2016
7.3.2 Financial Overview
Table 33: Boehringher Ingelheim Net Sales; 2012-2016 (US$ Billion)
Table 34: Boehringher Ingelheim Net Sales by Geography; 2016 (Percentage, %)
Table 35: Boehringher Ingelheim Net Sales by Business; 2016 (Percentage, %)
7.3.3 Business Strategy
7.4 Daiichi Sankyo
7.4.1 Business Overview
7.4.2 Financial Overview
Table 36: Daiichi Sankyo Revenue; 2012-2017 (US$ Billion)
Table 37: Daiichi Sankyo Revenue by Geography; 2017 (Percentage, %)
7.4.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report